• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe autoimmune intravascular hemolytic anemia in patients receiving alemtuzumab for multiple sclerosis.

作者信息

Sharma Parth, Saksena Annapurna, Diaz Adolfo, Pang Yifan, Desai Parth

机构信息

Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO.

Department of Hematopathology, National Institutes of Health, Bethesda, MD.

出版信息

Blood Adv. 2023 Jun 13;7(11):2534-2537. doi: 10.1182/bloodadvances.2022008968.

DOI:10.1182/bloodadvances.2022008968
PMID:36375041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10248092/
Abstract
摘要

相似文献

1
Severe autoimmune intravascular hemolytic anemia in patients receiving alemtuzumab for multiple sclerosis.接受阿仑单抗治疗多发性硬化症的患者出现严重自身免疫性血管内溶血性贫血。
Blood Adv. 2023 Jun 13;7(11):2534-2537. doi: 10.1182/bloodadvances.2022008968.
2
Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion.阿仑单抗输注后出现自身免疫性溶血性贫血、脱髓鞘复发及水通道蛋白1抗体
Neurol Neuroimmunol Neuroinflamm. 2020 Apr 2;7(3). doi: 10.1212/NXI.0000000000000711. Print 2020 May.
3
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.在使用阿仑单抗治疗多发性硬化症后，发生危及生命的自身免疫性温性溶血性贫血。
Mult Scler. 2018 May;24(6):811-813. doi: 10.1177/1352458517729766. Epub 2018 Jan 23.
4
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.在使用阿仑单抗治疗多发性硬化症期间同时出现早期严重自身免疫性溶血性贫血和蛋白尿。
Mult Scler. 2018 May;24(6):813-815. doi: 10.1177/1352458517743093. Epub 2018 Jan 23.
5
Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature.一名多发性硬化症（MS）患者使用芬戈莫德治疗后发生自身免疫性溶血性贫血：病例报告及文献综述
Autoimmun Rev. 2022 Dec;21(12):103203. doi: 10.1016/j.autrev.2022.103203. Epub 2022 Oct 8.
6
Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: A case report.阿仑单抗诱导的自身免疫性溶血性贫血、肺泡出血、肾病和中风同时发作：一例报告。
Mult Scler Relat Disord. 2020 Jun;41:102141. doi: 10.1016/j.msard.2020.102141. Epub 2020 Apr 22.
7
Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report.获得性血友病 A 作为多发性硬化症阿仑单抗治疗后的继发自身免疫性疾病：一例报告。
Mult Scler Relat Disord. 2019 Jan;27:403-405. doi: 10.1016/j.msard.2018.11.029. Epub 2018 Nov 29.
8
Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.在胰腺移植受者中，使用阿仑单抗、霉酚酸酯和达利珠单抗进行免疫抑制后出现的纯红细胞再生障碍和自身免疫性溶血性贫血。
Haematologica. 2007 Aug;92(8):1029-36. doi: 10.3324/haematol.10733. Epub 2007 Jul 20.
9
Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.干扰素-β-1b治疗多发性硬化症期间出现的自身免疫性溶血性贫血。
Mult Scler. 2007 Jun;13(5):683-5. doi: 10.1177/1352458506071333. Epub 2007 Mar 15.
10
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Mult Scler. 2013 Oct;19(11):1551-2. doi: 10.1177/1352458513493035. Epub 2013 Jul 1.

本文引用的文献

1
Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.在复发缓解型多发性硬化症中使用阿仑单抗治疗后的免疫调节细胞偏向。
Front Immunol. 2021 Oct 28;12:706278. doi: 10.3389/fimmu.2021.706278. eCollection 2021.
2
Autoimmune Hemolytic Anemias.自身免疫性溶血性贫血
N Engl J Med. 2021 Oct 7;385(15):1407-1419. doi: 10.1056/NEJMra2033982.
3
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.阿仑单抗6年的疗效与安全性：4年CARE-MS扩展试验的最终结果
Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134. doi: 10.1177/1756286420982134. eCollection 2021.
4
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.在 RRMS 患者中使用阿仑单抗的长期疗效和安全性：CAMMS223 的 12 年随访结果。
J Neurol. 2020 Nov;267(11):3343-3353. doi: 10.1007/s00415-020-09983-1. Epub 2020 Jun 24.
5
Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: A case report.阿仑单抗诱导的自身免疫性溶血性贫血、肺泡出血、肾病和中风同时发作：一例报告。
Mult Scler Relat Disord. 2020 Jun;41:102141. doi: 10.1016/j.msard.2020.102141. Epub 2020 Apr 22.
6
Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion.阿仑单抗输注后出现自身免疫性溶血性贫血、脱髓鞘复发及水通道蛋白1抗体
Neurol Neuroimmunol Neuroinflamm. 2020 Apr 2;7(3). doi: 10.1212/NXI.0000000000000711. Print 2020 May.
7
Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT).同种异体造血干细胞移植后自身免疫性血细胞减少症（AIC）：欧洲血液和骨髓移植学会（EBMT）自身免疫疾病和严重再生障碍性贫血工作组（ADWP/SAAWP）的联合研究。
Bone Marrow Transplant. 2020 Feb;55(2):441-451. doi: 10.1038/s41409-019-0680-4. Epub 2019 Sep 25.
8
Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.监测和管理接受阿仑单抗治疗的多发性硬化症患者的自身免疫：实用建议。
J Neurol. 2018 Nov;265(11):2494-2505. doi: 10.1007/s00415-018-8822-y. Epub 2018 Mar 10.
9
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.在使用阿仑单抗治疗多发性硬化症期间同时出现早期严重自身免疫性溶血性贫血和蛋白尿。
Mult Scler. 2018 May;24(6):813-815. doi: 10.1177/1352458517743093. Epub 2018 Jan 23.
10
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.在使用阿仑单抗治疗多发性硬化症后，发生危及生命的自身免疫性温性溶血性贫血。
Mult Scler. 2018 May;24(6):811-813. doi: 10.1177/1352458517729766. Epub 2018 Jan 23.